Could a new drug beat the current standard for septic shock?

NCT ID NCT06746753

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called Angiotensin II works better than the usual treatment (norepinephrine) for people with septic shock, a life-threatening condition where blood pressure drops dangerously. About 78 adults with septic shock will receive either Angiotensin II or standard care to see which helps restore blood pressure and improve survival. The goal is to find better ways to treat this serious illness and reduce its high death rate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney disorder Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27157, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital-Harvard

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact Email: •••••@•••••

    Contact